Daré Bioscience (NASDAQ: DARE) updates investor presentation and furnishes 8-K
Rhea-AI Filing Summary
Daré Bioscience, Inc. furnished a current report to let investors know it has posted an updated corporate presentation on its investor relations website. The presentation is dated March 2, 2026 and is also attached as Exhibit 99.1 to the report for convenient access.
The company states that this investor presentation is being furnished under Regulation FD, not filed, which means it is not subject to certain securities law liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. No financial results or new transaction details are described in the excerpt.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
DARÉ BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On March 2, 2026, Daré Bioscience, Inc. (“Daré” or the “Company”) made available an updated corporate presentation in the “Investors” section of its website (https://ir.darebioscience.com). A copy of the presentation, dated March 2, 2026, is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
The information in this Item 7.01 and Exhibit 99.1 to this report is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.
Information contained in, or that can be accessed through, the Company’s website or any other website referenced in its corporate presentation is not incorporated by reference into this report.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Daré Bioscience corporate presentation, dated March 2, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| DARÉ BIOSCIENCE, INC. | ||
| Dated: March 2, 2026 | By: | /s/ Sabrina Martucci Johnson |
| Name: | Sabrina Martucci Johnson | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
FAQ
What did Daré Bioscience (DARE) disclose in its latest 8-K filing?
Where can investors access Daré Bioscience’s updated March 2, 2026 presentation?
How is Daré Bioscience’s March 2, 2026 investor presentation treated under securities laws?
What exhibits were included with Daré Bioscience’s March 2, 2026 current report?
Does Daré Bioscience incorporate website information into this current report?
Filing Exhibits & Attachments
34 documentsPress Releases
- EX-99.1 EX-99.1 38.1 KB
- EX-99 GRAPHIC 219.0 KB
- EX-99 GRAPHIC 3.1 MB
- EX-99 GRAPHIC 307.7 KB
- EX-99 GRAPHIC 316.6 KB
- EX-99 GRAPHIC 596.4 KB
- EX-99 GRAPHIC 452.9 KB
- EX-99 GRAPHIC 310.1 KB
- EX-99 GRAPHIC 444.0 KB
- EX-99 GRAPHIC 392.2 KB
- EX-99 GRAPHIC 434.7 KB
- EX-99 GRAPHIC 431.4 KB
- EX-99 GRAPHIC 420.5 KB
- EX-99 GRAPHIC 277.1 KB
- EX-99 GRAPHIC 282.6 KB
- EX-99 GRAPHIC 274.5 KB
- EX-99 GRAPHIC 258.0 KB
- EX-99 GRAPHIC 461.5 KB
- EX-99 GRAPHIC 535.4 KB
- EX-99 GRAPHIC 741.0 KB
- EX-99 GRAPHIC 659.6 KB
- EX-99 GRAPHIC 539.7 KB
- EX-99 GRAPHIC 649.0 KB
- EX-99 GRAPHIC 605.7 KB
- EX-99 GRAPHIC 507.1 KB
- EX-99 GRAPHIC 587.0 KB
- EX-99 GRAPHIC 574.8 KB
- EX-99 GRAPHIC 635.4 KB
- EX-99 GRAPHIC 511.5 KB
- EX-99 GRAPHIC 525.3 KB
- EX-99 GRAPHIC 179.5 KB
